Skip to main content
OpenTrials
Completed

NCT Number: NCT04625673

OsciPulse Device for the Prevention of VTE

This is a Phase 2 safety and tolerability trial that will take place in two parts. Part one of the trial will determine the tolerability of the OsciPulse device on healthy subjects who wear the device for up to three hours. Healthy volunteers will answer questionnaires and may undergo an ultrasound test at the end of their participation in the trial.

Part two of the trial will determine the safety and tolerability of the OsciPulse device on subjects admitted to Penn Presbyterian Medical Center. Eligible subjects will be enrolled for 6 hours. In the first 3 hours, subjects will wear the standard of care intermittent pneumatic compression device or the OsciPulse device. In the second 3 hours, the subject's device will be switched and subjects will wear the alternate device not used in the first 3 hours. Subjects will answer questionnaires and may undergo an ultrasound at the end of the first 3 hours and at the end of the second 3 hours (at hour 6).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Venous Thromboembolism Cardiovascular Diseases Deep Vein Thrombosis Embolism Embolism and Thrombosis Lung Diseases Pulmonary Embolism Pulmonary Thromboembolisms Respiratory Tract Diseases Thromboembolism Thrombosis Vascular Diseases Venous Thrombosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Penn Presbyterian Medical Center

Philadelphia, Pennsylvania, 19104, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Part 1: Adult over the age of 40, generally healthy without a current foot or ankle injury, no history of diagnosed vascular disease including DVT, PE, VTE, post-phlebetic syndrome, or chronic venous insufficiency, mentally alert and understand English proficiently, able to give informed consent

Part 2: Adult over the age of 18, admitted to the at Penn Presbyterian Medical Center, anticipated decreased level of mobility for at least 6 hours as determined by the clinical team in collaboration with study personnel, mentally alert and understand English proficiently, able to give informed consent.

Exclusion criteria

Part 1: injury to the lower limbs, skin breaks, abrasion, or irritation in the area of the limb in contact with the OsciPulse device.

Part 2:

  • Inability or contraindication to applying IPC to both legs such as:
  • Evidence of bone fracture in lower extremities
  • Burns in the lower extremities, lacerations, ulcers, active skin infection or dermatitis, & ischemic limb in the legs at the site of IPC placement
  • Acute ischemia in the lower extremities
  • Severe peripheral vascular disease
  • Amputated foot or leg on one or two sides
  • Compartment syndrome
  • Severe lower extremity edema
  • Subjects anticipated to require surgical intervention within six (6) hours of admission
  • Subjects with history of VTE (DVT or PE)
  • Previous vascular surgery
  • Pregnancy or within 6 weeks of postpartum period
  • Limitation of life support, life expectancy < 7 days or palliative care
  • Admitted to an outside hospital more than 24 hours prior to screening
  • A head-unit is unavailable for the 6 hours or more
  • At the discretion of the attending physician and / or clinical team, the subject's participation in the study is believed not to be in the best interest of the subject.

Treatment and study plan

OsciPulse

Device

OsciPulse device and standard IPC device

Other names: Standard IPC device

Primary outcomes

  1. Part 1 - Subject's Response to Tolerability Questionnaire

    Time frame: up to 3 hours

    Tolerability will be measured by subject's response to questionnaires to assess their experience with the device. This will be measured on a linear 100 mm visual acuity scale measured in millimeters. Subjects are provided with the scale and asked to make a mark on the line that corresponds to their experience with the device. The least favorable rating is on the left hand side, the most favorable rating is on the right hand side of the scale. The mark on the line is measured in millimeters, resulting in least favorable scores having a lower score, and most favorable ratings having a higher score.

  2. Part 1 - Safety Assessment Through Collection of Adverse Events

    Time frame: up to 3 hours

    Safety will be assessed by collecting & reviewing all adverse events while subject is wearing the device.

    Subjects will indicate if the device caused 1) no discomfort, 2) mild discomfort, or 3) significant discomfort. To move on to Part 2, all subjects in Part 1 must indicate that there was not "significant discomfort."

  3. Part 2 - Subject's Response to Tolerability Questionnaire

    Time frame: 6 hours

    Tolerability will be measured by subject's response to questionnaires to assess their experience with the device. This will be measured on a linear 100mm visual acuity scale measured in millimeters. Subjects are provided with the scale and asked to make a mark on the line that corresponds to their experience with the device. The minimum (least favorable) rating is on the left hand side and is equal to zero (0), the maximum (most favorable) rating is on the right hand side of the scale and is equal to one hundred (100). For Comfort, scores range from "very disruptive" (0) to "no effect" (10). For Disruption, scores range from "very disruptive" (0) to "no effect" (10). For Noise, scores range from "very loud" (0) to "not noticeable" (10). For Movement, scores range from "very restrictive" (0) to "no effect" (10). The mark on the line is measured in millimeters, resulting in minimum (least favorable) scores having a lower score, and maximum (most favorable) ratings having a higher score.

  4. Part 2 - Safety Assessment Through Collection of Adverse Events.

    Time frame: 6 hours

    Safety will be assessed by collecting all adverse events while the subject is wearing the device.

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Collaborators

  • OsciFlex LLC

Registry information

Official study title

Phase 2, Randomized Study of the Tolerability and Safety of the OsciPulse Device for the Prevention of VTE

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Nov 12, 2020
Registry last updated
Nov 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.